Polycystic Ovarian Disease (PCOD) A Comprehensive Review

Polycystic ovarian disease (PCOD), often interchangeably referred to in the literature as Polycystic Ovary Syndrome, represents one of the most common and complex endocrine-metabolic disorders affecting women during their reproductive years. It is characterized by a constellation of reproductive, endocrine, metabolic, and psychological abnormalities, including chronic anovulation, menstrual irregularities, hyperandrogenism, polycystic ovarian morphology, obesity, insulin resistance, infertility, and emotional disturbances [1]. The condition is considered a heterogeneous syndrome due to the wide variation in clinical manifestations, severity, and long-term complications among affected individuals. This heterogeneity makes diagnosis and management particularly challenging for clinicians and researchers. The syndrome was first described in 1935 by Irving F. Stein Sr. and Michael L. Leventhal, who reported a series of women presenting with amenorrhea, infertility, and enlarged polycystic ovaries, subsequently termed Stein-Leventhal syndrome [2]. Since this initial description, scientific understanding of the disorder has evolved substantially. What was once regarded as a purely gynecological condition is now recognized as a multisystem endocrine and metabolic disorder with lifelong implications extending beyond reproductive health. Globally, PCOD affects approximately 6–20% of women of reproductive age depending on the diagnostic criteria applied, such as the European Society of Human Reproduction and Embryology / American Society for Reproductive Medicine Rotterdam criteria, the National Institutes of Health criteria, or the Androgen Excess and PCOS Society criteria [3]. The prevalence appears to be particularly high in South Asian populations, including India, where rapid urbanization, sedentary lifestyles, altered dietary patterns, and genetic susceptibility contribute significantly to disease incidence [4]. The increasing prevalence among adolescent girls has emerged as a major public health concern due to its potential impact on future fertility and metabolic health. The pathophysiology of PCOD is multifactorial and incompletely understood, involving intricate interactions between genetic, epigenetic, hormonal, metabolic, and environmental factors. Central to its pathogenesis is dysfunction of the hypothalamic-pituitary-ovarian (HPO) axis, which leads to increased secretion of luteinizing hormone (LH) relative to follicle-stimulating hormone (FSH), promoting ovarian androgen overproduction [5]. Hyperandrogenism disrupts normal follicular maturation and ovulation, resulting in the accumulation of immature follicles that appear as cysts on ultrasonography. Insulin resistance is another hallmark feature observed in a majority of women with PCOD, independent of obesity status. Hyperinsulinemia resulting from insulin resistance amplifies ovarian androgen synthesis and suppresses hepatic production of sex hormone-binding globulin (SHBG), thereby increasing circulating free androgen levels [6]. This interaction between insulin resistance and hyperandrogenism establishes a vicious cycle that perpetuates disease progression. Additionally, chronic low-grade inflammation and oxidative stress have been implicated in the pathogenesis of PCOD, contributing to both reproductive and metabolic dysfunction [7]. Clinically, PCOD manifests with a broad spectrum of symptoms that may vary significantly among individuals. Common reproductive manifestations include oligomenorrhea, amenorrhea, anovulation, infertility, and recurrent miscarriage. Hyperandrogenic symptoms such as hirsutism, acne, and androgenic alopecia are also frequently observed. Metabolic abnormalities including central obesity, dyslipidemia, impaired glucose tolerance, and increased risk of type 2 diabetes mellitus further complicate the syndrome [8]. Beyond physical symptoms, women with PCOD often experience psychological comorbidities such as depression, anxiety, body image dissatisfaction, and reduced quality of life.

The diagnosis of PCOD remains complex because no single test can definitively establish the condition. Instead, diagnosis relies on a combination of clinical evaluation, biochemical hormonal assessment, and imaging studies. The widely accepted Rotterdam criteria require the presence of at least two of the following: oligo/anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasonography [9]. However, diagnostic controversies persist due to variability in phenotypic presentation and overlap with other endocrine disorders such as thyroid dysfunction, hyperprolactinemia, and congenital adrenal hyperplasia. Management of PCOD is equally multifaceted and depends on the patient's symptoms, age, fertility goals, and metabolic profile. Current therapeutic approaches include lifestyle modifications, insulin sensitizers such as Metformin, hormonal contraceptives, ovulation induction agents, and anti-androgen therapies [10]. In recent years, increasing interest has focused on complementary and alternative medicine, particularly herbal therapeutics and nutraceutical interventions, due to their potential multi-targeted benefits with fewer adverse effects. Simultaneously, nanotechnology-based drug delivery systems are emerging as promising strategies for enhancing therapeutic efficacy and targeted ovarian delivery.

2. Epidemiology and Global Burden

2.1 Global Prevalence of Polycystic Ovarian Disease

Polycystic ovarian disease (PCOD) is one of the most prevalent endocrine disorders among women of reproductive age and constitutes a significant healthcare concern worldwide. Epidemiological studies indicate that its prevalence varies substantially depending on the diagnostic criteria used, population characteristics, and geographical distribution. According to available global data, the prevalence of PCOD ranges between 4% and 20%, making it among the most frequently diagnosed hormonal disorders in gynecological practice [11]. The variability in prevalence is largely due to differences in diagnostic standards. The National Institutes of Health criteria report relatively lower prevalence because they require both hyperandrogenism and ovulatory dysfunction for diagnosis. Conversely, the European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine Rotterdam criteria include polycystic ovarian morphology as an additional diagnostic parameter, thereby identifying a broader spectrum of affected individuals [12].

Table 1: Prevalence According to Diagnostic Criteria

This broad prevalence spectrum highlights the heterogeneous nature of the disorder and underscores the need for standardized global diagnostic frameworks.

2.2 Regional Distribution and Geographical Variability

The occurrence of PCOD demonstrates marked geographical variation, reflecting differences in genetic predisposition, environmental influences, socioeconomic conditions, and lifestyle practices.

Table 2: Regional Distribution of PCOD

South Asian populations, particularly women from India, exhibit a notably higher prevalence compared to Western populations [13]. This elevated burden is believed to result from a combination of genetic susceptibility to insulin resistance, high carbohydrate dietary patterns, sedentary behavior, and increasing urbanization. The prevalence in urban populations is often significantly greater than in rural communities, emphasizing the influence of modernization and changing lifestyle habits on disease occurrence.

2.3 Age-Wise Distribution

PCOD can manifest at different stages of reproductive life, though symptoms most commonly appear during adolescence or early adulthood. Age-specific epidemiological studies reveal distinct clinical presentations across life stages.

Table 3: Age-Specific Clinical Features

Adolescents frequently present with irregular menstrual cycles and acne, while women in their twenties and thirties often seek medical attention due to infertility or cosmetic concerns related to hyperandrogenism [14]. Early identification is crucial because delayed diagnosis may predispose individuals to long-term reproductive and metabolic complications.

2.4 Epidemiology of PCOD in Adolescents

The prevalence of PCOD among adolescents has shown a notable increase over the last decade. This trend is concerning because adolescence represents a critical period for endocrine maturation. Recent studies indicate that between 9% and 26% of adolescent girls in urban populations exhibit features suggestive of PCOD [15]. The rise is primarily attributed to increasing childhood obesity, poor dietary habits, physical inactivity, and heightened exposure to environmental endocrine disruptors. Diagnosing PCOD in adolescents is challenging because physiological pubertal changes often mimic pathological symptoms. Menstrual irregularities and transient acne are common during puberty, making differentiation difficult.

The early onset of PCOD is associated with greater risk of:

• Persistent infertility
• Severe insulin resistance
• Early-onset metabolic syndrome
• Psychological distress

2.5 Ethnic and Genetic Variability

Ethnicity significantly influences both the prevalence and clinical phenotype of PCOD.

South Asian women often display:

• More pronounced insulin resistance
• Higher abdominal adiposity
• Earlier disease onset

Caucasian women more commonly exhibit:

• Severe hyperandrogenism
• Classical hirsutism

East Asian women frequently present with:

• Menstrual irregularities
• Lower obesity prevalence
• Milder androgenic manifestations [16]

These differences suggest a strong interplay between ethnicity-specific genetic determinants and environmental exposures.

Table 4: Ethnic Variability in Clinical Features

Understanding ethnic variability is essential for personalized diagnostic and therapeutic approaches.

2.6 Economic Burden of PCOD

PCOD imposes substantial economic strain on healthcare systems worldwide due to its chronic nature and associated long-term complications.

The direct costs include:

• Hormonal investigations
• Ultrasonography
• Pharmacological treatment
• Fertility therapies

Indirect costs arise from:

• Reduced workplace productivity
• Psychological counseling
• Long-term diabetes management

In the United States, annual healthcare expenditure attributable to PCOD exceeds $4 billion [17]. In developing countries, the economic burden is often magnified by limited access to affordable specialist care and infertility management services.

2.7 Psychological and Social Burden

The psychosocial consequences of PCOD are often underrecognized despite their substantial impact on quality of life.

Women with PCOD exhibit significantly higher rates of:

• Anxiety disorders
• Depression
• Low self-esteem
• Social isolation
• Eating disorders [18]

The visible manifestations of the syndrome, such as hirsutism, obesity, and acne, often contribute to negative body image and reduced confidence.

Infertility-related distress can be particularly severe in cultures where motherhood is strongly associated with social identity and acceptance.

2.8 Long-Term Global Health Burden

PCOD is increasingly recognized as a lifelong metabolic disorder rather than solely a reproductive condition.

Women with PCOD face elevated risks of:

Table 5: Long-Term Health Risks

The burden of these associated disorders significantly contributes to morbidity and healthcare costs worldwide [19].

2.9 Public Health Challenges

Despite its high prevalence, PCOD remains underdiagnosed.

Key barriers include:

Diagnostic ambiguity due to overlapping symptoms with other endocrine disorders, limited awareness among adolescents, inadequate screening programs, and cultural hesitation in discussing reproductive health issues [20]. In low-resource settings, delayed diagnosis often leads to advanced disease presentation.

2.10 Future Epidemiological Trends

The global prevalence of PCOD is expected to rise due to increasing obesity rates, urbanization, environmental endocrine disruptor exposure, and lifestyle transitions.

Future projections suggest that without effective preventive strategies, the syndrome will contribute substantially to rising infertility rates and metabolic disease burden globally [21]. This growing epidemiological challenge emphasizes the urgent need for:

• Early screening
• Lifestyle interventions
• Public awareness campaigns
• Improved healthcare accessibility

3. Etiology and Pathophysiology

3.1 Multifactorial Etiology of PCOD

Polycystic ovarian disease is a multifactorial endocrine-metabolic disorder resulting from the complex interaction of genetic, hormonal, metabolic, environmental, and lifestyle-related factors. Unlike monogenic disorders, PCOD does not arise from a single identifiable cause; instead, it is considered a polygenic and heterogeneous syndrome involving dysregulation across multiple physiological systems [22]. The etiology is influenced by intrinsic factors such as inherited susceptibility and endocrine dysfunction, as well as extrinsic factors including sedentary lifestyle, obesity, nutritional imbalance, psychological stress, and environmental endocrine disruptors. These factors interact to disturb normal ovarian physiology, leading to chronic anovulation and hyperandrogenism.

3.2 Genetic Predisposition

Genetic susceptibility plays a central role in the development of PCOD. Familial clustering of the disorder strongly suggests heritable components, with first-degree female relatives of affected individuals showing significantly increased risk [23]. Several candidate genes associated with PCOD include those involved in:

• Ovarian steroidogenesis
• Insulin signaling
• Gonadotropin regulation
• Inflammatory pathways

Important implicated genes include:

Table 6 : Genes Associated with PCOD

Mutations or polymorphisms in these genes alter endocrine homeostasis and predispose individuals to disease development.

3.3 Hypothalamic-Pituitary-Ovarian Axis Dysfunction

One of the hallmark pathophysiological mechanisms in PCOD involves dysregulation of the hypothalamic-pituitary-ovarian (HPO) axis. Under physiological conditions, the hypothalamus secretes Gonadotropin-Releasing Hormone, which stimulates pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In PCOD, increased pulsatile secretion of this hormone leads to elevated LH secretion relative to FSH [24]. This altered LH/FSH ratio promotes excessive androgen production by ovarian theca cells while impairing granulosa cell-mediated follicular maturation.

Consequences include:

• Arrested follicular development
• Failure of ovulation
• Accumulation of immature follicles
• Polycystic ovarian morphology

3.4 Hyperandrogenism

Hyperandrogenism is the defining endocrine abnormality in PCOD and is responsible for many clinical manifestations. Excessive ovarian androgen production occurs primarily due to overstimulation of theca cells by elevated LH and hyperinsulinemia [25].

Key circulating androgens include:

• Testosterone
• Androstenedione
• Dehydroepiandrosterone sulfate (DHEAS)

Elevated androgen levels lead to:

Table 7: Effects of Hyperandrogenism

Persistent androgen excess disrupts follicular development and contributes to infertility.

3.5 Insulin Resistance and Hyperinsulinemia

Insulin resistance is observed in approximately 50–70% of women with PCOD and is considered a major pathogenic contributor [26]. In this condition, peripheral tissues become less responsive to insulin, compelling pancreatic β-cells to secrete larger quantities of insulin to maintain glucose homeostasis.

Hyperinsulinemia exacerbates PCOD through several mechanisms:

• Stimulating ovarian androgen synthesis
• Reducing hepatic production of sex hormone-binding globulin
• Increasing free testosterone levels
• Enhancing LH action on ovarian tissue

This creates a self-perpetuating cycle between insulin resistance and hyperandrogenism.

3.6 Role of Chronic Inflammation and Oxidative Stress

Emerging evidence identifies chronic low-grade inflammation as a significant contributor to PCOD pathophysiology.

Women with PCOD exhibit elevated levels of inflammatory mediators including:

• TNF-α
• IL-6
• C-reactive protein [27]

These inflammatory molecules impair insulin signaling and worsen ovarian dysfunction. Simultaneously, oxidative stress generated by excessive reactive oxygen species damages ovarian tissue, impairs folliculogenesis, and accelerates disease progression.

3.7 Environmental and Lifestyle Factors

Environmental factors significantly modulate disease expression.

Contributing factors include:

• High-calorie diets
• Physical inactivity
• Psychological stress
• Exposure to endocrine-disrupting chemicals such as Bisphenol A

These factors amplify metabolic disturbances and may trigger disease manifestation in genetically predisposed individuals [28].

Figure 1. Etiology and Pathophysiological Mechanisms of Polycystic Ovarian Disease (PCOD): Integrated Overview of Genetic, Environmental, Metabolic, and Endocrine Factors

4. Molecular Mechanisms in PCOD

4.1 Molecular Basis

The molecular mechanisms underlying Polycystic Ovary Syndrome involve intricate interactions between endocrine signaling pathways, metabolic regulation, inflammatory cascades, and genetic susceptibility. At the molecular level, PCOD is characterized by abnormalities in ovarian steroidogenesis, insulin receptor signaling, mitochondrial function, oxidative stress regulation, and cellular communication pathways [29]. These molecular alterations contribute to the characteristic features of hyperandrogenism, chronic anovulation, insulin resistance, and polycystic ovarian morphology. Understanding these mechanisms is essential for identifying novel therapeutic targets and improving precision-based treatment strategies.

4.2 Dysregulation of Ovarian Steroidogenesis

One of the most prominent molecular abnormalities in PCOD is excessive androgen biosynthesis due to dysregulated ovarian steroidogenesis.

The ovarian theca cells demonstrate increased activity of steroidogenic enzymes, particularly:

• CYP11A1
• CYP17A1
• 3β-HSD
• StAR protein

These enzymes are responsible for converting cholesterol into androgen precursors [30].

Table 8 : Key Steroidogenic Enzymes in PCOD

Overexpression of these enzymes leads to excessive androgen secretion, which disrupts normal follicular maturation and promotes follicular arrest.

4.3 Insulin Signaling Pathway Abnormalities

Insulin resistance in PCOD is closely linked to defects in post-receptor insulin signaling. Under normal physiological conditions, insulin binds to the Insulin Receptor, activating intracellular signaling cascades such as:

• PI3K/Akt pathway
• MAPK pathway

In women with PCOD, serine phosphorylation of insulin receptor substrates impairs downstream signaling, resulting in reduced glucose uptake and metabolic dysfunction [31].

This molecular defect contributes to:

• Hyperinsulinemia
• Increased ovarian androgen synthesis
• Impaired glucose metabolism

Hyperinsulinemia further stimulates ovarian theca cells, exacerbating androgen overproduction.

4.4 PI3K/Akt Signaling Dysfunction

The PI3K/Akt Signaling Pathway plays a critical role in glucose transport, cellular growth, and ovarian follicular development.

In PCOD, impaired activation of this pathway leads to:

• Reduced glucose transporter translocation
• Decreased insulin sensitivity
• Altered follicular cell survival
• Impaired ovulation [32]

Suppression of PI3K/Akt signaling also contributes to increased apoptosis of granulosa cells, which are essential for healthy follicular maturation.

Table 9 : Effects of PI3K/Akt Dysfunction

This molecular disruption links metabolic abnormalities directly to reproductive dysfunction.

4.5 AMPK Pathway Suppression

AMP-Activated Protein Kinase is a crucial regulator of energy homeostasis.

AMPK activation promotes:

• Glucose uptake
• Fatty acid oxidation
• Reduction in androgen synthesis

In PCOD, decreased AMPK activity contributes to metabolic dysfunction and excessive ovarian steroidogenesis [33].

Suppression of this pathway results in:

• Increased lipid accumulation
• Enhanced insulin resistance
• Ovarian dysfunction

The therapeutic efficacy of Metformin is partly attributed to activation of AMPK signaling.

4.6 Oxidative Stress and Mitochondrial Dysfunction

Mitochondrial dysfunction has emerged as a major molecular contributor to PCOD pathogenesis. Abnormal mitochondrial activity leads to excessive generation of reactive oxygen species (ROS), causing oxidative damage to ovarian cells [34].

This oxidative stress affects:

• Oocyte quality
• Granulosa cell viability
• Follicular maturation
• Hormonal balance

Table 10 : Molecular Effects of Oxidative Stress

Persistent oxidative stress worsens both reproductive and metabolic features of PCOD.

4.7 Inflammatory Signaling Pathways

Chronic low-grade inflammation in PCOD is mediated through activation of inflammatory molecular pathways.

Important inflammatory mediators include:

• TNF-α
• IL-6
• NF-κB
• CRP

Activation of the NF-kappa B pathway promotes cytokine release and insulin resistance [35].

These inflammatory pathways contribute to:

• Ovarian dysfunction
• Endothelial damage
• Metabolic syndrome progression

Inflammation also amplifies oxidative stress, creating a pathological feedback loop.

4.8 Epigenetic Modifications

Epigenetic changes influence gene expression without altering DNA sequence.

Major epigenetic mechanisms implicated in PCOD include:

• DNA methylation
• Histone modification
• microRNA dysregulation

Altered expression of specific microRNAs affects:

• Insulin sensitivity
• Steroidogenesis
• Inflammatory regulation [36]

These modifications may explain phenotypic variability and transgenerational susceptibility.

4.9 Gut Microbiota and Molecular Crosstalk

Recent evidence suggests that gut microbiota composition influences PCOD through molecular communication with endocrine and metabolic pathways.

Gut dysbiosis contributes to:

• Increased intestinal permeability
• Endotoxemia
• Systemic inflammation
• Insulin resistance [37]

Microbial metabolites modulate ovarian function through the gut-brain-ovary axis.

This emerging area offers promising therapeutic possibilities through microbiome-targeted interventions.

4.10 Integrated Molecular Network

PCOD arises from interconnected molecular disturbances rather than isolated abnormalities.

The major interacting mechanisms include:

• Steroidogenic dysregulation
• Insulin signaling impairment
• Oxidative stress
• Inflammation
• Epigenetic alterations

These molecular events collectively drive disease progression and determine clinical severity [38].

A deeper understanding of these pathways is essential for developing personalized therapeutic strategies.

5. Clinical Manifestations

5.1 Clinical Presentation

The clinical manifestations of Polycystic Ovary Syndrome are highly variable and reflect the complex interplay between endocrine dysfunction, metabolic disturbances, and reproductive abnormalities. The syndrome exhibits marked phenotypic heterogeneity, meaning that no two affected individuals present with identical symptoms. Clinical features may vary according to age, ethnicity, obesity status, severity of hyperandrogenism, and degree of insulin resistance [39]. The manifestations of PCOD generally become apparent during adolescence or early reproductive years and may evolve over time. Some women predominantly present with reproductive dysfunction, whereas others exhibit severe metabolic disturbances or cosmetic manifestations. The major clinical features include menstrual irregularities, hyperandrogenic symptoms, infertility, metabolic complications, and psychological disturbances.

5.2 Menstrual Irregularities

Menstrual dysfunction is one of the earliest and most common manifestations of PCOD. It results primarily from chronic anovulation caused by disrupted follicular maturation and hormonal imbalance.

The most common menstrual abnormalities include:

Oligomenorrhea: Menstrual cycles longer than 35 days

Amenorrhea: Absence of menstruation for three or more consecutive months

Irregular menstrual cycles: Unpredictable cycle intervals

Heavy or prolonged bleeding: Resulting from unopposed estrogen stimulation of the endometrium

These abnormalities arise due to disturbed secretion of Luteinizing Hormone and Follicle-Stimulating Hormone, which impair ovulation [40].

Persistent menstrual irregularity increases the risk of endometrial hyperplasia due to prolonged estrogen exposure without progesterone-mediated endometrial shedding.

5.3 Hyperandrogenic Manifestations

Hyperandrogenism is a defining clinical hallmark of PCOD and results from excessive androgen production by ovarian theca cells.

The most common androgenic manifestations include:

Hirsutism

Hirsutism refers to excessive terminal hair growth in androgen-sensitive areas such as:

• Face
• Chin
• Chest
• Abdomen
• Lower back

It is one of the most distressing cosmetic symptoms and affects approximately 60–80% of women with PCOD [41].

Acne

Androgen excess stimulates sebaceous gland activity, leading to increased sebum production and acne development.

PCOD-related acne is often:

• Persistent
• Severe
• Resistant to conventional treatment

Androgenic Alopecia

Some women experience male-pattern hair loss characterized by thinning over the frontal scalp and vertex region. The severity of these manifestations varies among ethnic groups, with certain populations demonstrating more pronounced androgenic features.

5.4 Ovulatory Dysfunction and Infertility

Ovulatory dysfunction is one of the most clinically significant reproductive manifestations of PCOD.

Normal ovulation depends on coordinated follicular maturation, which is disrupted in PCOD due to hormonal imbalance.

Consequences include:

• Chronic anovulation
• Delayed ovulation
• Poor oocyte quality
• Infertility

PCOD accounts for nearly 70–80% of cases of anovulatory infertility worldwide [42].

Affected women may experience difficulty conceiving due to:

• Irregular ovulation
• Hormonal imbalance
• Impaired endometrial receptivity

Even when conception occurs, PCOD is associated with increased risks of:

• Early miscarriage
• Gestational diabetes
• Pregnancy-induced hypertension

These reproductive challenges significantly impact emotional well-being and quality of life.

5.5 Obesity and Body Composition Changes

Obesity is frequently associated with PCOD, particularly central or abdominal obesity. Approximately 40–70% of women with PCOD are overweight or obese [43].

The characteristic pattern involves increased visceral adiposity, which contributes to:

• Insulin resistance
• Hyperinsulinemia
• Inflammation
• Exacerbation of hyperandrogenism

This establishes a vicious metabolic cycle that worsens disease severity.

Women with normal body mass index may also exhibit metabolically unfavorable fat distribution, emphasizing that obesity is not essential for diagnosis.

5.6 Metabolic Manifestations

PCOD is increasingly recognized as a metabolic disorder.

The most common metabolic abnormalities include:

Insulin Resistance

Present in a majority of affected women, independent of obesity.

Impaired Glucose Tolerance

Women with PCOD are at significantly increased risk of developing prediabetes.

Type 2 Diabetes Mellitus

The lifetime risk of developing Type 2 Diabetes is markedly elevated [44].

Dyslipidemia

Common lipid abnormalities include:

• Elevated triglycerides
• Reduced HDL cholesterol
• Increased LDL cholesterol

Metabolic Syndrome

PCOD substantially increases the risk of metabolic syndrome, characterized by the coexistence of:

• Abdominal obesity
• Hypertension
• Hyperglycemia
• Dyslipidemia

These abnormalities significantly increase long-term cardiovascular risk.

5.7 Dermatological Manifestations

Several dermatological findings accompany PCOD.

Acanthosis Nigricans

This condition appears as dark, velvety skin thickening commonly observed on:

• Neck
• Axilla
• Groin

It is strongly associated with insulin resistance.

Seborrhea

Excess androgen activity stimulates sebaceous gland secretion.

Skin Tags

Often observed in women with significant metabolic dysfunction.

These skin changes may serve as early visible indicators of underlying endocrine disturbances [45].

5.8 Psychological Manifestations

Psychological disturbances are highly prevalent in women with PCOD and often remain underdiagnosed.

Common mental health manifestations include:

Depression

Chronic symptoms, infertility, and cosmetic concerns contribute to depressive disorders.

Anxiety

Uncertainty regarding fertility and body image often leads to persistent anxiety.

Body Image Disturbance

Visible symptoms such as obesity, acne, and hirsutism negatively affect self-perception.

Reduced Quality of Life

Women frequently report impairment in:

• Social functioning
• Sexual health
• Emotional well-being [46]

The psychosocial burden may sometimes exceed the physical burden of the disorder.

5.9 Sleep Disturbances

Women with PCOD exhibit increased prevalence of sleep-related disorders.

These include:

• Insomnia
• Poor sleep quality
• Daytime fatigue
• Obstructive sleep apnea

Obesity and insulin resistance significantly contribute to these disturbances [47].

Sleep dysfunction further aggravates metabolic and hormonal imbalance.

5.10 Long-Term Clinical Consequences

Untreated PCOD may progress to significant long-term complications.

These include:

Endometrial hyperplasia and carcinoma due to prolonged unopposed estrogen exposure

Cardiovascular disease resulting from metabolic syndrome

Infertility persistence

Chronic psychological morbidity

Type 2 diabetes progression

The broad clinical spectrum of PCOD emphasizes the need for early recognition and multidisciplinary management [48].

6. Diagnostic Approaches

6.1 Diagnosis

The diagnosis of Polycystic Ovary Syndrome remains one of the most challenging aspects of clinical management due to its heterogeneous presentation and overlap with other endocrine disorders. Unlike diseases with a single definitive biomarker, PCOD is diagnosed through a combination of clinical assessment, biochemical investigations, imaging findings, and exclusion of other pathological conditions [49].

The diagnostic complexity arises because manifestations vary widely across age groups, ethnic populations, and phenotypic subtypes. Some women primarily present with reproductive dysfunction, while others exhibit metabolic abnormalities or hyperandrogenic symptoms. Consequently, accurate diagnosis requires a multidisciplinary and systematic evaluation.

The primary goals of diagnosis include:

• Confirming the presence of PCOD
• Excluding other endocrine disorders
• Assessing severity of metabolic dysfunction
• Identifying reproductive complications
• Guiding individualized treatment strategies

Early diagnosis is particularly important because timely intervention can significantly reduce long-term reproductive and metabolic complications.

6.2 Diagnostic Criteria for PCOD

Several diagnostic criteria have been proposed for PCOD, each emphasizing different aspects of the syndrome.

6.2.1 NIH Criteria (1990)

The National Institutes of Health criteria were among the earliest standardized diagnostic guidelines.

According to these criteria, diagnosis requires the presence of:

• Chronic anovulation
• Clinical or biochemical hyperandrogenism

Other related disorders must be excluded.

Although highly specific, these criteria may underdiagnose milder phenotypes because they do not consider polycystic ovarian morphology [50].

6.2.2 Rotterdam Criteria (2003)

The Rotterdam criteria, developed by European Society of Human Reproduction and Embryology and American Society for Reproductive Medicine, are currently the most widely accepted diagnostic standard.

Diagnosis requires the presence of any two of the following three features:

Oligo-ovulation or anovulation

Clinical or biochemical hyperandrogenism

Polycystic ovarian morphology on ultrasonography

This broader framework allows recognition of multiple phenotypic variants [51].

The Rotterdam criteria classify PCOD into four phenotypes:

Phenotype A: Hyperandrogenism + ovulatory dysfunction + polycystic ovaries

Phenotype B: Hyperandrogenism + ovulatory dysfunction

Phenotype C: Hyperandrogenism + polycystic ovaries

Phenotype D: Ovulatory dysfunction + polycystic ovaries

This classification improves clinical characterization and treatment planning.

6.2.3 Androgen Excess Society Criteria

The Androgen Excess and PCOS Society emphasizes hyperandrogenism as the essential diagnostic feature.

Diagnosis requires:

• Hyperandrogenism
• Ovarian dysfunction and/or polycystic ovaries

This criterion is considered more pathophysiologically focused because androgen excess is central to disease development [52].

6.3 Clinical Evaluation

Clinical assessment forms the foundation of diagnosis.

A detailed patient history should evaluate:

Menstrual history

Frequency, duration, and regularity of cycles

Reproductive history

Infertility, miscarriages, ovulation-related issues

Family history

Presence of PCOD, diabetes, obesity, infertility

Lifestyle factors

Diet, physical activity, stress

Physical examination should focus on identifying clinical signs of hyperandrogenism and metabolic dysfunction.

Important findings include:

• Hirsutism
• Acne
• Alopecia
• Obesity
• Acanthosis nigricans
• Central adiposity

The Ferriman-Gallwey Score is commonly used to quantify hirsutism severity [53].

6.4 Biochemical Assessment

Laboratory evaluation is essential for confirming hormonal abnormalities and excluding differential diagnoses.

6.4.1 Hormonal Investigations

Key hormonal tests include measurement of:

Total and free testosterone

Elevated levels indicate hyperandrogenism.

Dehydroepiandrosterone sulfate (DHEAS)

Helps identify adrenal androgen excess.

Luteinizing hormone (LH)

Often elevated.

Follicle-stimulating hormone (FSH)

May remain normal or reduced.

An elevated LH/FSH ratio is suggestive but not diagnostic.

Prolactin

Used to exclude hyperprolactinemia.

Thyroid-stimulating hormone (TSH)

Excludes thyroid dysfunction [54].

6.4.2 Metabolic Investigations

Because PCOD is strongly associated with metabolic abnormalities, metabolic screening is mandatory.

Recommended investigations include:

Fasting blood glucose

Oral glucose tolerance test

Fasting insulin levels

Lipid profile

HbA1c

These tests help detect:

• Insulin resistance
• Prediabetes
• Diabetes mellitus
• Dyslipidemia

Metabolic screening should be repeated periodically due to progressive disease risk [55].

6.5 Ultrasonographic Evaluation

Pelvic ultrasonography is a crucial imaging modality for assessing ovarian morphology.

Characteristic findings include:

• Enlarged ovarian volume
• Multiple peripheral follicles
• Dense stromal tissue

According to updated criteria, polycystic ovarian morphology is defined as:

At least 20 follicles per ovary or ovarian volume exceeding 10 mL [56].

Transvaginal ultrasonography offers superior resolution and is preferred in sexually active women.

Transabdominal ultrasonography is often used in adolescents and unmarried patients. It is important to note that polycystic ovarian morphology alone does not confirm diagnosis, as similar findings may occur in healthy women.

6.6 Differential Diagnosis

Several endocrine disorders mimic PCOD and must be excluded.

These include:

Congenital Adrenal Hyperplasia

Cushing Syndrome

Hyperprolactinemia

Hypothyroidism

Androgen-secreting tumors

Differentiation is essential because management strategies differ significantly [57].

6.7 Diagnostic Challenges in Adolescents

Diagnosing PCOD during adolescence is particularly difficult.

Physiological pubertal changes often resemble pathological features such as:

• Irregular menstruation
• Acne
• Multifollicular ovaries

Experts recommend cautious interpretation and repeated follow-up before establishing diagnosis [58]. Overdiagnosis can result in unnecessary anxiety, whereas delayed diagnosis may postpone intervention.

6.8 Emerging Diagnostic Biomarkers

Research is exploring novel biomarkers for earlier and more accurate diagnosis.

Promising candidates include:

Anti-Müllerian Hormone

Often elevated in PCOD due to increased follicle number.

Inflammatory cytokines

Reflect metabolic disturbance.

MicroRNAs

Potential molecular signatures.

Metabolomic markers

Provide insight into disease phenotype [59].

These biomarkers may improve diagnostic precision in the future.

6.9 Role of Artificial Intelligence in Diagnosis

Artificial intelligence and machine learning are emerging tools in PCOD diagnosis.

Applications include:

• Ultrasound image analysis
• Hormonal pattern recognition
• Risk prediction modeling
• Phenotype classification

AI-based systems may improve early detection and reduce diagnostic variability [60].

6.10 Importance of Early Diagnosis

Timely diagnosis allows:

• Early lifestyle intervention
• Prevention of infertility
• Reduction of metabolic complications
• Improved quality of life

A comprehensive diagnostic approach integrating clinical, biochemical, and imaging evaluation remains essential for optimal patient management.

7. Conventional Therapeutic Strategies

7.1 Therapeutic Management

The management of Polycystic Ovary Syndrome is complex and requires an individualized, multidisciplinary approach due to the heterogeneity of its clinical manifestations. Since PCOD affects reproductive, metabolic, endocrine, and psychological health, therapeutic interventions are primarily directed toward symptom control, prevention of long-term complications, restoration of ovulation, improvement of insulin sensitivity, and enhancement of quality of life [61]. There is currently no definitive cure for PCOD; therefore, treatment strategies focus on managing specific symptoms according to the patient’s age, reproductive goals, metabolic profile, and severity of clinical manifestations.

The major therapeutic objectives include:

• Regulation of menstrual cycles
• Reduction of hyperandrogenic symptoms
• Improvement of fertility
• Management of insulin resistance
• Prevention of cardiovascular and metabolic complications
• Psychological support

Conventional therapeutic strategies involve lifestyle interventions, pharmacological management, ovulation induction, anti-androgen therapy, and surgical interventions when necessary.

7.2 Lifestyle Modification

Lifestyle modification is universally regarded as the first-line treatment for PCOD, particularly in overweight and obese women. Lifestyle interventions target the underlying metabolic disturbances responsible for disease progression.

Key components include:

Dietary Modification

Nutritional management focuses on reducing insulin resistance and promoting sustainable weight reduction.

Recommended dietary strategies include:

• Low glycemic index diets
• High-fiber intake
• Reduced refined carbohydrate consumption
• Balanced protein-fat distribution
• Calorie-controlled nutrition plans

A low glycemic diet improves insulin sensitivity and reduces circulating androgen levels [62].

Physical Activity

Regular exercise significantly improves metabolic and reproductive outcomes.

Recommended forms include:

• Aerobic exercise
• Resistance training
• High-intensity interval training
• Yoga and flexibility exercises

Exercise improves:

• Insulin sensitivity
• Weight management
• Menstrual regularity
• Psychological well-being

Weight Reduction

A modest reduction of 5–10% of body weight can produce substantial clinical improvement.

Benefits include:

• Restoration of ovulation
• Improved fertility
• Reduced androgen levels
• Better metabolic profile

Lifestyle modification remains the most cost-effective and sustainable therapeutic strategy.

7.3 Combined Oral Contraceptive Pills

Combined oral contraceptive pills (COCPs) are commonly prescribed for women who do not currently desire pregnancy.

These agents contain estrogen and progestin combinations such as:

Ethinyl estradiol

Drospirenone

Cyproterone acetate

COCPs exert therapeutic effects by:

• Suppressing ovarian androgen production
• Increasing sex hormone-binding globulin
• Reducing free testosterone levels
• Regulating menstrual cycles

Clinical benefits include:

• Improved menstrual regularity
• Reduction in acne
• Improvement in hirsutism
• Prevention of endometrial hyperplasia [63]

However, prolonged use may be associated with:

• Weight gain
• Mood changes
• Increased thromboembolic risk in predisposed individuals

Careful patient selection is therefore essential.

7.4 Insulin Sensitizing Agents

Insulin resistance is central to PCOD pathogenesis, making insulin sensitizers a cornerstone of therapy.

7.4.1 Metformin

Metformin is the most widely used insulin sensitizer in PCOD management.

Its primary mechanisms include:

• Activation of AMP-Activated Protein Kinase
• Reduction of hepatic gluconeogenesis
• Improvement of peripheral glucose uptake
• Reduction of hyperinsulinemia

Clinical benefits include:

• Improved insulin sensitivity
• Restoration of ovulation
• Reduction in androgen levels
• Weight stabilization
• Improvement in menstrual regularity [64]

Metformin is especially beneficial in women with:

• Obesity
• Prediabetes
• Type 2 diabetes risk
• Metabolic syndrome

Common adverse effects include gastrointestinal discomfort and nausea.

7.4.2 Thiazolidinediones

Agents such as Pioglitazone improve insulin sensitivity through activation of peroxisome proliferator-activated receptor gamma.

Benefits include:

• Improved ovulation
• Reduced insulin resistance
• Better glucose metabolism

However, concerns regarding weight gain and cardiovascular safety limit widespread use [65].

7.5 Ovulation Induction Therapy

For women seeking conception, ovulation induction is a primary therapeutic objective.

7.5.1 Clomiphene Citrate

Clomiphene citrate has long been the traditional first-line ovulation induction agent.

Mechanism of action:

It blocks estrogen receptors at the hypothalamus, increasing gonadotropin secretion.

Benefits include:

• Ovulation induction
• Improved conception rates

Limitations include:

• Clomiphene resistance
• Risk of multiple pregnancy
• Thin endometrial lining [66]

7.5.2 Letrozole

Letrozole has emerged as the preferred first-line ovulation induction therapy.

Mechanism:

It inhibits estrogen synthesis, increasing follicle-stimulating hormone release.

Advantages over clomiphene include:

• Higher ovulation rates
• Better pregnancy outcomes
• Lower multiple pregnancy risk [67]

Recent clinical guidelines favor letrozole for infertility management in PCOD.

7.6 Anti-Androgen Therapy

Anti-androgens are used to manage cosmetic manifestations.

Common agents include:

Spironolactone

Flutamide

Finasteride

These medications reduce:

• Hirsutism
• Acne
• Alopecia

Because of teratogenic potential, anti-androgens should be used with effective contraception [68].

7.7 Gonadotropin Therapy

Women resistant to oral ovulation induction may require injectable gonadotropins.

These stimulate follicular development directly.

Benefits include:

• High ovulation success

Risks include:

• Ovarian hyperstimulation syndrome
• Multiple pregnancy
• Intensive monitoring requirements [69]

7.8 Surgical Management

Surgical intervention is reserved for selected cases.

7.8.1 Laparoscopic Ovarian Drilling

This minimally invasive procedure involves puncturing ovarian tissue to reduce androgen-producing stromal activity.

Benefits include:

• Restoration of ovulation
• Reduced LH levels
• Improved fertility

Limitations include:

• Adhesion formation
• Reduced ovarian reserve if excessive drilling occurs [70]

It is generally considered after failure of pharmacological therapy.

7.9 Management of Psychological Symptoms

Psychological care is increasingly recognized as essential.

Management strategies include:

• Cognitive behavioral therapy
• Stress reduction techniques
• Counseling
• Support groups

Addressing psychological health improves treatment adherence and overall quality of life [71].

7.10 Long-Term Monitoring

Because PCOD is a chronic condition, long-term monitoring is necessary.

Recommended follow-up includes:

• Blood glucose monitoring
• Lipid profile assessment
• Blood pressure evaluation
• Endometrial surveillance
• Mental health screening

Continuous monitoring enables early detection of complications.

7.11 Limitations of Conventional Therapy

Despite therapeutic advances, conventional treatments have limitations.

These include:

• Symptom recurrence after discontinuation
• Adverse drug effects
• Limited efficacy in resistant cases
• Incomplete correction of underlying pathophysiology

These limitations have encouraged exploration of novel therapies including herbal interventions and nanotechnology-based delivery systems [72].

CONCLUSION

PCOD is a multifaceted endocrine-metabolic disorder requiring integrated management. Advances in molecular biology have elucidated key mechanisms involving insulin resistance, hyperandrogenism, inflammation, and epigenetic regulation. Conventional pharmacotherapy remains effective; however, limitations necessitate innovative strategies including herbal therapeutics, nanotechnology-based delivery systems, precision medicine, and AI-driven diagnostics. Future research should emphasize individualized treatment approaches and long-term disease prevention to improve reproductive and metabolic outcomes. Polycystic ovarian disease (PCOD), often interchangeably referred to in the literature as Polycystic Ovary Syndrome, represents one of the most common and complex endocrine-metabolic disorders affecting women during their reproductive years. It is characterized by a constellation of reproductive, endocrine, metabolic, and psychological abnormalities, including chronic anovulation, menstrual irregularities, hyperandrogenism, polycystic ovarian morphology, obesity, insulin resistance, infertility, and emotional disturbances [1]. The condition is considered a heterogeneous syndrome due to the wide variation in clinical manifestations, severity, and long-term complications among affected individuals. This heterogeneity makes diagnosis and management particularly challenging for clinicians and researchers. The syndrome was first described in 1935 by Irving F. Stein Sr. and Michael L. Leventhal, who reported a series of women presenting with amenorrhea, infertility, and enlarged polycystic ovaries, subsequently termed Stein-Leventhal syndrome [2]. Since this initial description, scientific understanding of the disorder has evolved substantially. What was once regarded as a purely gynecological condition is now recognized as a multisystem endocrine and metabolic disorder with lifelong implications extending beyond reproductive health. Globally, PCOD affects approximately 6–20% of women of reproductive age depending on the diagnostic criteria applied, such as the European Society of Human Reproduction and Embryology / American Society for Reproductive Medicine Rotterdam criteria, the National Institutes of Health criteria, or the Androgen Excess and PCOS Society criteria [3]. The prevalence appears to be particularly high in South Asian populations, including India, where rapid urbanization, sedentary lifestyles, altered dietary patterns, and genetic susceptibility contribute significantly to disease incidence [4]. The increasing prevalence among adolescent girls has emerged as a major public health concern due to its potential impact on future fertility and metabolic health. The pathophysiology of PCOD is multifactorial and incompletely understood, involving intricate interactions between genetic, epigenetic, hormonal, metabolic, and environmental factors. Central to its pathogenesis is dysfunction of the hypothalamic-pituitary-ovarian (HPO) axis, which leads to increased secretion of luteinizing hormone (LH) relative to follicle-stimulating hormone (FSH), promoting ovarian androgen overproduction [5]. Hyperandrogenism disrupts normal follicular maturation and ovulation, resulting in the accumulation of immature follicles that appear as cysts on ultrasonography. Insulin resistance is another hallmark feature observed in a majority of women with PCOD, independent of obesity status. Hyperinsulinemia resulting from insulin resistance amplifies ovarian androgen synthesis and suppresses hepatic production of sex hormone-binding globulin (SHBG), thereby increasing circulating free androgen levels [6]. This interaction between insulin resistance and hyperandrogenism establishes a vicious cycle that perpetuates disease progression. Additionally, chronic low-grade inflammation and oxidative stress have been implicated in the pathogenesis of PCOD, contributing to both reproductive and metabolic dysfunction [7]. Clinically, PCOD manifests with a broad spectrum of symptoms that may vary significantly among individuals. Common reproductive manifestations include oligomenorrhea, amenorrhea, anovulation, infertility, and recurrent miscarriage. Hyperandrogenic symptoms such as hirsutism, acne, and androgenic alopecia are also frequently observed. Metabolic abnormalities including central obesity, dyslipidemia, impaired glucose tolerance, and increased risk of type 2 diabetes mellitus further complicate the syndrome [8]. Beyond physical symptoms, women with PCOD often experience psychological comorbidities such as depression, anxiety, body image dissatisfaction, and reduced quality of life.

The diagnosis of PCOD remains complex because no single test can definitively establish the condition. Instead, diagnosis relies on a combination of clinical evaluation, biochemical hormonal assessment, and imaging studies. The widely accepted Rotterdam criteria require the presence of at least two of the following: oligo/anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasonography [9]. However, diagnostic controversies persist due to variability in phenotypic presentation and overlap with other endocrine disorders such as thyroid dysfunction, hyperprolactinemia, and congenital adrenal hyperplasia. Management of PCOD is equally multifaceted and depends on the patient's symptoms, age, fertility goals, and metabolic profile. Current therapeutic approaches include lifestyle modifications, insulin sensitizers such as Metformin, hormonal contraceptives, ovulation induction agents, and anti-androgen therapies [10]. In recent years, increasing interest has focused on complementary and alternative medicine, particularly herbal therapeutics and nutraceutical interventions, due to their potential multi-targeted benefits with fewer adverse effects. Simultaneously, nanotechnology-based drug delivery systems are emerging as promising strategies for enhancing therapeutic efficacy and targeted ovarian delivery.

2. Epidemiology and Global Burden

2.1 Global Prevalence of Polycystic Ovarian Disease

Polycystic ovarian disease (PCOD) is one of the most prevalent endocrine disorders among women of reproductive age and constitutes a significant healthcare concern worldwide. Epidemiological studies indicate that its prevalence varies substantially depending on the diagnostic criteria used, population characteristics, and geographical distribution. According to available global data, the prevalence of PCOD ranges between 4% and 20%, making it among the most frequently diagnosed hormonal disorders in gynecological practice [11]. The variability in prevalence is largely due to differences in diagnostic standards. The National Institutes of Health criteria report relatively lower prevalence because they require both hyperandrogenism and ovulatory dysfunction for diagnosis. Conversely, the European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine Rotterdam criteria include polycystic ovarian morphology as an additional diagnostic parameter, thereby identifying a broader spectrum of affected individuals [12].

Table 1: Prevalence According to Diagnostic Criteria

This broad prevalence spectrum highlights the heterogeneous nature of the disorder and underscores the need for standardized global diagnostic frameworks.

2.2 Regional Distribution and Geographical Variability

The occurrence of PCOD demonstrates marked geographical variation, reflecting differences in genetic predisposition, environmental influences, socioeconomic conditions, and lifestyle practices.

Table 2: Regional Distribution of PCOD

South Asian populations, particularly women from India, exhibit a notably higher prevalence compared to Western populations [13]. This elevated burden is believed to result from a combination of genetic susceptibility to insulin resistance, high carbohydrate dietary patterns, sedentary behavior, and increasing urbanization. The prevalence in urban populations is often significantly greater than in rural communities, emphasizing the influence of modernization and changing lifestyle habits on disease occurrence.

2.3 Age-Wise Distribution

PCOD can manifest at different stages of reproductive life, though symptoms most commonly appear during adolescence or early adulthood. Age-specific epidemiological studies reveal distinct clinical presentations across life stages.

Table 3: Age-Specific Clinical Features

Adolescents frequently present with irregular menstrual cycles and acne, while women in their twenties and thirties often seek medical attention due to infertility or cosmetic concerns related to hyperandrogenism [14]. Early identification is crucial because delayed diagnosis may predispose individuals to long-term reproductive and metabolic complications.

2.4 Epidemiology of PCOD in Adolescents

The prevalence of PCOD among adolescents has shown a notable increase over the last decade. This trend is concerning because adolescence represents a critical period for endocrine maturation. Recent studies indicate that between 9% and 26% of adolescent girls in urban populations exhibit features suggestive of PCOD [15]. The rise is primarily attributed to increasing childhood obesity, poor dietary habits, physical inactivity, and heightened exposure to environmental endocrine disruptors. Diagnosing PCOD in adolescents is challenging because physiological pubertal changes often mimic pathological symptoms. Menstrual irregularities and transient acne are common during puberty, making differentiation difficult.

The early onset of PCOD is associated with greater risk of:

• Persistent infertility
• Severe insulin resistance
• Early-onset metabolic syndrome
• Psychological distress

2.5 Ethnic and Genetic Variability

Ethnicity significantly influences both the prevalence and clinical phenotype of PCOD.

South Asian women often display:

• More pronounced insulin resistance
• Higher abdominal adiposity
• Earlier disease onset

Caucasian women more commonly exhibit:

• Severe hyperandrogenism
• Classical hirsutism

East Asian women frequently present with:

• Menstrual irregularities
• Lower obesity prevalence
• Milder androgenic manifestations [16]

These differences suggest a strong interplay between ethnicity-specific genetic determinants and environmental exposures.

Table 4: Ethnic Variability in Clinical Features

Understanding ethnic variability is essential for personalized diagnostic and therapeutic approaches.

2.6 Economic Burden of PCOD

PCOD imposes substantial economic strain on healthcare systems worldwide due to its chronic nature and associated long-term complications.

The direct costs include:

• Hormonal investigations
• Ultrasonography
• Pharmacological treatment
• Fertility therapies

Indirect costs arise from:

• Reduced workplace productivity
• Psychological counseling
• Long-term diabetes management

In the United States, annual healthcare expenditure attributable to PCOD exceeds $4 billion [17].

In developing countries, the economic burden is often magnified by limited access to affordable specialist care and infertility management services.

2.7 Psychological and Social Burden

The psychosocial consequences of PCOD are often underrecognized despite their substantial impact on quality of life.

Women with PCOD exhibit significantly higher rates of:

• Anxiety disorders
• Depression
• Low self-esteem
• Social isolation
• Eating disorders [18]

The visible manifestations of the syndrome, such as hirsutism, obesity, and acne, often contribute to negative body image and reduced confidence.

Infertility-related distress can be particularly severe in cultures where motherhood is strongly associated with social identity and acceptance.

2.8 Long-Term Global Health Burden

PCOD is increasingly recognized as a lifelong metabolic disorder rather than solely a reproductive condition.

Women with PCOD face elevated risks of:

Table 5: Long-Term Health Risks

The burden of these associated disorders significantly contributes to morbidity and healthcare costs worldwide [19].

2.9 Public Health Challenges

Despite its high prevalence, PCOD remains underdiagnosed.

Key barriers include:

Diagnostic ambiguity due to overlapping symptoms with other endocrine disorders, limited awareness among adolescents, inadequate screening programs, and cultural hesitation in discussing reproductive health issues [20]. In low-resource settings, delayed diagnosis often leads to advanced disease presentation.

2.10 Future Epidemiological Trends

The global prevalence of PCOD is expected to rise due to increasing obesity rates, urbanization, environmental endocrine disruptor exposure, and lifestyle transitions. Future projections suggest that without effective preventive strategies, the syndrome will contribute substantially to rising infertility rates and metabolic disease burden globally [21].

This growing epidemiological challenge emphasizes the urgent need for:

• Early screening
• Lifestyle interventions
• Public awareness campaigns
• Improved healthcare accessibility

3. Etiology and Pathophysiology

3.1 Multifactorial Etiology of PCOD

Polycystic ovarian disease is a multifactorial endocrine-metabolic disorder resulting from the complex interaction of genetic, hormonal, metabolic, environmental, and lifestyle-related factors. Unlike monogenic disorders, PCOD does not arise from a single identifiable cause; instead, it is considered a polygenic and heterogeneous syndrome involving dysregulation across multiple physiological systems [22]. The etiology is influenced by intrinsic factors such as inherited susceptibility and endocrine dysfunction, as well as extrinsic factors including sedentary lifestyle, obesity, nutritional imbalance, psychological stress, and environmental endocrine disruptors. These factors interact to disturb normal ovarian physiology, leading to chronic anovulation and hyperandrogenism.

3.2 Genetic Predisposition

Genetic susceptibility plays a central role in the development of PCOD. Familial clustering of the disorder strongly suggests heritable components, with first-degree female relatives of affected individuals showing significantly increased risk [23].

Several candidate genes associated with PCOD include those involved in:

• Ovarian steroidogenesis
• Insulin signaling
• Gonadotropin regulation
• Inflammatory pathways

Important implicated genes include:

Table 6 : Genes Associated with PCOD

Mutations or polymorphisms in these genes alter endocrine homeostasis and predispose individuals to disease development.

3.3 Hypothalamic-Pituitary-Ovarian Axis Dysfunction

One of the hallmark pathophysiological mechanisms in PCOD involves dysregulation of the hypothalamic-pituitary-ovarian (HPO) axis. Under physiological conditions, the hypothalamus secretes Gonadotropin-Releasing Hormone, which stimulates pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In PCOD, increased pulsatile secretion of this hormone leads to elevated LH secretion relative to FSH [24]. This altered LH/FSH ratio promotes excessive androgen production by ovarian theca cells while impairing granulosa cell-mediated follicular maturation.

Consequences include:

• Arrested follicular development
• Failure of ovulation
• Accumulation of immature follicles
• Polycystic ovarian morphology

3.4 Hyperandrogenism

Hyperandrogenism is the defining endocrine abnormality in PCOD and is responsible for many clinical manifestations. Excessive ovarian androgen production occurs primarily due to overstimulation of theca cells by elevated LH and hyperinsulinemia [25].

Key circulating androgens include:

• Testosterone
• Androstenedione
• Dehydroepiandrosterone sulfate (DHEAS)

Elevated androgen levels lead to:

Table 7: Effects of Hyperandrogenism

Persistent androgen excess disrupts follicular development and contributes to infertility.

3.5 Insulin Resistance and Hyperinsulinemia

Insulin resistance is observed in approximately 50–70% of women with PCOD and is considered a major pathogenic contributor [26]. In this condition, peripheral tissues become less responsive to insulin, compelling pancreatic β-cells to secrete larger quantities of insulin to maintain glucose homeostasis.

Hyperinsulinemia exacerbates PCOD through several mechanisms:

• Stimulating ovarian androgen synthesis
• Reducing hepatic production of sex hormone-binding globulin
• Increasing free testosterone levels
• Enhancing LH action on ovarian tissue

This creates a self-perpetuating cycle between insulin resistance and hyperandrogenism.

3.6 Role of Chronic Inflammation and Oxidative Stress

Emerging evidence identifies chronic low-grade inflammation as a significant contributor to PCOD pathophysiology.

Women with PCOD exhibit elevated levels of inflammatory mediators including:

• TNF-α
• IL-6
• C-reactive protein [27]

These inflammatory molecules impair insulin signaling and worsen ovarian dysfunction.

Simultaneously, oxidative stress generated by excessive reactive oxygen species damages ovarian tissue, impairs folliculogenesis, and accelerates disease progression.

3.7 Environmental and Lifestyle Factors

Environmental factors significantly modulate disease expression.

Contributing factors include:

• High-calorie diets
• Physical inactivity
• Psychological stress
• Exposure to endocrine-disrupting chemicals such as Bisphenol A

These factors amplify metabolic disturbances and may trigger disease manifestation in genetically predisposed individuals [28].

4. Molecular Mechanisms in PCOD

4.1 Molecular Basis

The molecular mechanisms underlying Polycystic Ovary Syndrome involve intricate interactions between endocrine signaling pathways, metabolic regulation, inflammatory cascades, and genetic susceptibility. At the molecular level, PCOD is characterized by abnormalities in ovarian steroidogenesis, insulin receptor signaling, mitochondrial function, oxidative stress regulation, and cellular communication pathways [29]. These molecular alterations contribute to the characteristic features of hyperandrogenism, chronic anovulation, insulin resistance, and polycystic ovarian morphology. Understanding these mechanisms is essential for identifying novel therapeutic targets and improving precision-based treatment strategies.

4.2 Dysregulation of Ovarian Steroidogenesis

One of the most prominent molecular abnormalities in PCOD is excessive androgen biosynthesis due to dysregulated ovarian steroidogenesis.

The ovarian theca cells demonstrate increased activity of steroidogenic enzymes, particularly:

• CYP11A1
• CYP17A1
• 3β-HSD
• StAR protein

These enzymes are responsible for converting cholesterol into androgen precursors [30].

Table 8 : Key Steroidogenic Enzymes in PCOD

Overexpression of these enzymes leads to excessive androgen secretion, which disrupts normal follicular maturation and promotes follicular arrest.

4.3 Insulin Signaling Pathway Abnormalities

Insulin resistance in PCOD is closely linked to defects in post-receptor insulin signaling.

Under normal physiological conditions, insulin binds to the Insulin Receptor, activating intracellular signaling cascades such as:

• PI3K/Akt pathway
• MAPK pathway

In women with PCOD, serine phosphorylation of insulin receptor substrates impairs downstream signaling, resulting in reduced glucose uptake and metabolic dysfunction [31].

This molecular defect contributes to:

• Hyperinsulinemia
• Increased ovarian androgen synthesis
• Impaired glucose metabolism

Hyperinsulinemia further stimulates ovarian theca cells, exacerbating androgen overproduction.

4.4 PI3K/Akt Signaling Dysfunction

The PI3K/Akt Signaling Pathway plays a critical role in glucose transport, cellular growth, and ovarian follicular development.

In PCOD, impaired activation of this pathway leads to:

• Reduced glucose transporter translocation
• Decreased insulin sensitivity
• Altered follicular cell survival
• Impaired ovulation [32]

Suppression of PI3K/Akt signaling also contributes to increased apoptosis of granulosa cells, which are essential for healthy follicular maturation.

Table 9 : Effects of PI3K/Akt Dysfunction

This molecular disruption links metabolic abnormalities directly to reproductive dysfunction.

4.5 AMPK Pathway Suppression

AMP-Activated Protein Kinase is a crucial regulator of energy homeostasis.

AMPK activation promotes:

• Glucose uptake
• Fatty acid oxidation
• Reduction in androgen synthesis

In PCOD, decreased AMPK activity contributes to metabolic dysfunction and excessive ovarian steroidogenesis [33].

Suppression of this pathway results in:

• Increased lipid accumulation
• Enhanced insulin resistance
• Ovarian dysfunction

The therapeutic efficacy of Metformin is partly attributed to activation of AMPK signaling.

4.6 Oxidative Stress and Mitochondrial Dysfunction

Mitochondrial dysfunction has emerged as a major molecular contributor to PCOD pathogenesis. Abnormal mitochondrial activity leads to excessive generation of reactive oxygen species (ROS), causing oxidative damage to ovarian cells [34].

This oxidative stress affects:

• Oocyte quality
• Granulosa cell viability
• Follicular maturation
• Hormonal balance

Table 10 : Molecular Effects of Oxidative Stress

Persistent oxidative stress worsens both reproductive and metabolic features of PCOD.

4.7 Inflammatory Signaling Pathways

Chronic low-grade inflammation in PCOD is mediated through activation of inflammatory molecular pathways.

Important inflammatory mediators include:

• TNF-α
• IL-6
• NF-κB
• CRP

Activation of the NF-kappa B pathway promotes cytokine release and insulin resistance [35].

These inflammatory pathways contribute to:

• Ovarian dysfunction
• Endothelial damage
• Metabolic syndrome progression

Inflammation also amplifies oxidative stress, creating a pathological feedback loop.

4.8 Epigenetic Modifications

Epigenetic changes influence gene expression without altering DNA sequence.

Major epigenetic mechanisms implicated in PCOD include:

• DNA methylation
• Histone modification
• microRNA dysregulation

Altered expression of specific microRNAs affects:

• Insulin sensitivity
• Steroidogenesis
• Inflammatory regulation [36]

These modifications may explain phenotypic variability and transgenerational susceptibility.

4.9 Gut Microbiota and Molecular Crosstalk

Recent evidence suggests that gut microbiota composition influences PCOD through molecular communication with endocrine and metabolic pathways.

Gut dysbiosis contributes to:

• Increased intestinal permeability
• Endotoxemia
• Systemic inflammation
• Insulin resistance [37]

Microbial metabolites modulate ovarian function through the gut-brain-ovary axis. This emerging area offers promising therapeutic possibilities through microbiome-targeted interventions.

4.10 Integrated Molecular Network

PCOD arises from interconnected molecular disturbances rather than isolated abnormalities.

The major interacting mechanisms include:

• Steroidogenic dysregulation
• Insulin signaling impairment
• Oxidative stress
• Inflammation
• Epigenetic alterations

These molecular events collectively drive disease progression and determine clinical severity [38]. A deeper understanding of these pathways is essential for developing personalized therapeutic strategies.

5. Clinical Manifestations

5.1 Clinical Presentation

The clinical manifestations of Polycystic Ovary Syndrome are highly variable and reflect the complex interplay between endocrine dysfunction, metabolic disturbances, and reproductive abnormalities. The syndrome exhibits marked phenotypic heterogeneity, meaning that no two affected individuals present with identical symptoms. Clinical features may vary according to age, ethnicity, obesity status, severity of hyperandrogenism, and degree of insulin resistance [39]. The manifestations of PCOD generally become apparent during adolescence or early reproductive years and may evolve over time. Some women predominantly present with reproductive dysfunction, whereas others exhibit severe metabolic disturbances or cosmetic manifestations. The major clinical features include menstrual irregularities, hyperandrogenic symptoms, infertility, metabolic complications, and psychological disturbances.

5.2 Menstrual Irregularities

Menstrual dysfunction is one of the earliest and most common manifestations of PCOD. It results primarily from chronic anovulation caused by disrupted follicular maturation and hormonal imbalance.

The most common menstrual abnormalities include:

Oligomenorrhea: Menstrual cycles longer than 35 days

Amenorrhea: Absence of menstruation for three or more consecutive months

Irregular menstrual cycles: Unpredictable cycle intervals

Heavy or prolonged bleeding: Resulting from unopposed estrogen stimulation of the endometrium

These abnormalities arise due to disturbed secretion of Luteinizing Hormone and Follicle-Stimulating Hormone, which impair ovulation [40]. Persistent menstrual irregularity increases the risk of endometrial hyperplasia due to prolonged estrogen exposure without progesterone-mediated endometrial shedding.

5.3 Hyperandrogenic Manifestations

Hyperandrogenism is a defining clinical hallmark of PCOD and results from excessive androgen production by ovarian theca cells.

The most common androgenic manifestations include:

Hirsutism

Hirsutism refers to excessive terminal hair growth in androgen-sensitive areas such as:

• Face
• Chin
• Chest
• Abdomen
• Lower back

It is one of the most distressing cosmetic symptoms and affects approximately 60–80% of women with PCOD [41].

Acne

Androgen excess stimulates sebaceous gland activity, leading to increased sebum production and acne development.

PCOD-related acne is often:

• Persistent
• Severe
• Resistant to conventional treatment

Androgenic Alopecia

Some women experience male-pattern hair loss characterized by thinning over the frontal scalp and vertex region. The severity of these manifestations varies among ethnic groups, with certain populations demonstrating more pronounced androgenic features.

5.4 Ovulatory Dysfunction and Infertility

Ovulatory dysfunction is one of the most clinically significant reproductive manifestations of PCOD. Normal ovulation depends on coordinated follicular maturation, which is disrupted in PCOD due to hormonal imbalance.

Consequences include:

• Chronic anovulation
• Delayed ovulation
• Poor oocyte quality
• Infertility

PCOD accounts for nearly 70–80% of cases of anovulatory infertility worldwide [42].

Affected women may experience difficulty conceiving due to:

• Irregular ovulation
• Hormonal imbalance
• Impaired endometrial receptivity

Even when conception occurs, PCOD is associated with increased risks of:

• Early miscarriage
• Gestational diabetes
• Pregnancy-induced hypertension

These reproductive challenges significantly impact emotional well-being and quality of life.

5.5 Obesity and Body Composition Changes

Obesity is frequently associated with PCOD, particularly central or abdominal obesity. Approximately 40–70% of women with PCOD are overweight or obese [43].

The characteristic pattern involves increased visceral adiposity, which contributes to:

• Insulin resistance
• Hyperinsulinemia
• Inflammation
• Exacerbation of hyperandrogenism

This establishes a vicious metabolic cycle that worsens disease severity. Women with normal body mass index may also exhibit metabolically unfavorable fat distribution, emphasizing that obesity is not essential for diagnosis.

5.6 Metabolic Manifestations

PCOD is increasingly recognized as a metabolic disorder.

The most common metabolic abnormalities include:

Insulin Resistance

Present in a majority of affected women, independent of obesity.

Impaired Glucose Tolerance

Women with PCOD are at significantly increased risk of developing prediabetes.

Type 2 Diabetes Mellitus

The lifetime risk of developing Type 2 Diabetes is markedly elevated [44].

Dyslipidemia

Common lipid abnormalities include:

• Elevated triglycerides
• Reduced HDL cholesterol
• Increased LDL cholesterol

Metabolic Syndrome

PCOD substantially increases the risk of metabolic syndrome, characterized by the coexistence of:

• Abdominal obesity
• Hypertension
• Hyperglycemia
• Dyslipidemia

These abnormalities significantly increase long-term cardiovascular risk.

5.7 Dermatological Manifestations

Several dermatological findings accompany PCOD.

Acanthosis Nigricans

This condition appears as dark, velvety skin thickening commonly observed on:

• Neck
• Axilla
• Groin

It is strongly associated with insulin resistance.

Seborrhea

Excess androgen activity stimulates sebaceous gland secretion.

Skin Tags

Often observed in women with significant metabolic dysfunction.

These skin changes may serve as early visible indicators of underlying endocrine disturbances [45].

5.8 Psychological Manifestations

Psychological disturbances are highly prevalent in women with PCOD and often remain underdiagnosed.

Common mental health manifestations include:

Depression

Chronic symptoms, infertility, and cosmetic concerns contribute to depressive disorders.

Anxiety

Uncertainty regarding fertility and body image often leads to persistent anxiety.

Body Image Disturbance

Visible symptoms such as obesity, acne, and hirsutism negatively affect self-perception.

Reduced Quality of Life

Women frequently report impairment in:

• Social functioning
• Sexual health
• Emotional well-being [46]

The psychosocial burden may sometimes exceed the physical burden of the disorder.

5.9 Sleep Disturbances

Women with PCOD exhibit increased prevalence of sleep-related disorders.

These include:

• Insomnia
• Poor sleep quality
• Daytime fatigue
• Obstructive sleep apnea

Obesity and insulin resistance significantly contribute to these disturbances [47].

Sleep dysfunction further aggravates metabolic and hormonal imbalance.

5.10 Long-Term Clinical Consequences

Untreated PCOD may progress to significant long-term complications.

These include:

Endometrial hyperplasia and carcinoma due to prolonged unopposed estrogen exposure

Cardiovascular disease resulting from metabolic syndrome

Infertility persistence

Chronic psychological morbidity

Type 2 diabetes progression

The broad clinical spectrum of PCOD emphasizes the need for early recognition and multidisciplinary management [48].

6. Diagnostic Approaches

6.1 Diagnosis

The diagnosis of Polycystic Ovary Syndrome remains one of the most challenging aspects of clinical management due to its heterogeneous presentation and overlap with other endocrine disorders. Unlike diseases with a single definitive biomarker, PCOD is diagnosed through a combination of clinical assessment, biochemical investigations, imaging findings, and exclusion of other pathological conditions [49]. The diagnostic complexity arises because manifestations vary widely across age groups, ethnic populations, and phenotypic subtypes. Some women primarily present with reproductive dysfunction, while others exhibit metabolic abnormalities or hyperandrogenic symptoms. Consequently, accurate diagnosis requires a multidisciplinary and systematic evaluation.

The primary goals of diagnosis include:

• Confirming the presence of PCOD
• Excluding other endocrine disorders
• Assessing severity of metabolic dysfunction
• Identifying reproductive complications
• Guiding individualized treatment strategies

Early diagnosis is particularly important because timely intervention can significantly reduce long-term reproductive and metabolic complications.

6.2 Diagnostic Criteria for PCOD

Several diagnostic criteria have been proposed for PCOD, each emphasizing different aspects of the syndrome.

6.2.1 NIH Criteria (1990)

The National Institutes of Health criteria were among the earliest standardized diagnostic guidelines.

According to these criteria, diagnosis requires the presence of:

• Chronic anovulation
• Clinical or biochemical hyperandrogenism

Other related disorders must be excluded.

Although highly specific, these criteria may underdiagnose milder phenotypes because they do not consider polycystic ovarian morphology [50].

6.2.2 Rotterdam Criteria (2003)

The Rotterdam criteria, developed by European Society of Human Reproduction and Embryology and American Society for Reproductive Medicine, are currently the most widely accepted diagnostic standard.

Diagnosis requires the presence of any two of the following three features:

Oligo-ovulation or anovulation

Clinical or biochemical hyperandrogenism

Polycystic ovarian morphology on ultrasonography

This broader framework allows recognition of multiple phenotypic variants [51].

The Rotterdam criteria classify PCOD into four phenotypes:

Phenotype A: Hyperandrogenism + ovulatory dysfunction + polycystic ovaries

Phenotype B: Hyperandrogenism + ovulatory dysfunction

Phenotype C: Hyperandrogenism + polycystic ovaries

Phenotype D: Ovulatory dysfunction + polycystic ovaries

This classification improves clinical characterization and treatment planning.

6.2.3 Androgen Excess Society Criteria

The Androgen Excess and PCOS Society emphasizes hyperandrogenism as the essential diagnostic feature.

Diagnosis requires:

• Hyperandrogenism
• Ovarian dysfunction and/or polycystic ovaries

This criterion is considered more pathophysiologically focused because androgen excess is central to disease development [52].

6.3 Clinical Evaluation

Clinical assessment forms the foundation of diagnosis.

A detailed patient history should evaluate:

Menstrual history

Frequency, duration, and regularity of cycles

Reproductive history

Infertility, miscarriages, ovulation-related issues

Family history

Presence of PCOD, diabetes, obesity, infertility

Lifestyle factors

Diet, physical activity, stress

Physical examination should focus on identifying clinical signs of hyperandrogenism and metabolic dysfunction.

Important findings include:

• Hirsutism
• Acne
• Alopecia
• Obesity
• Acanthosis nigricans
• Central adiposity

The Ferriman-Gallwey Score is commonly used to quantify hirsutism severity [53].

6.4 Biochemical Assessment

Laboratory evaluation is essential for confirming hormonal abnormalities and excluding differential diagnoses.

6.4.1 Hormonal Investigations

Key hormonal tests include measurement of:

Total and free testosterone

Elevated levels indicate hyperandrogenism.

Dehydroepiandrosterone sulfate (DHEAS)

Helps identify adrenal androgen excess.

Luteinizing hormone (LH)

Often elevated.

Follicle-stimulating hormone (FSH)

May remain normal or reduced.

An elevated LH/FSH ratio is suggestive but not diagnostic.

Prolactin

Used to exclude hyperprolactinemia.

Thyroid-stimulating hormone (TSH)

Excludes thyroid dysfunction [54].

6.4.2 Metabolic Investigations

Because PCOD is strongly associated with metabolic abnormalities, metabolic screening is mandatory.

Recommended investigations include:

Fasting blood glucose

Oral glucose tolerance test

Fasting insulin levels

Lipid profile

HbA1c

These tests help detect:

• Insulin resistance
• Prediabetes
• Diabetes mellitus
• Dyslipidemia

Metabolic screening should be repeated periodically due to progressive disease risk [55].

6.5 Ultrasonographic Evaluation

Pelvic ultrasonography is a crucial imaging modality for assessing ovarian morphology.

Characteristic findings include:

• Enlarged ovarian volume
• Multiple peripheral follicles
• Dense stromal tissue

According to updated criteria, polycystic ovarian morphology is defined as:

At least 20 follicles per ovary or ovarian volume exceeding 10 mL [56].

Transvaginal ultrasonography offers superior resolution and is preferred in sexually active women.

Transabdominal ultrasonography is often used in adolescents and unmarried patients.

It is important to note that polycystic ovarian morphology alone does not confirm diagnosis, as similar findings may occur in healthy women.

6.6 Differential Diagnosis

Several endocrine disorders mimic PCOD and must be excluded.

These include:

Congenital Adrenal Hyperplasia

Cushing Syndrome

Hyperprolactinemia

Hypothyroidism

Androgen-secreting tumors

Differentiation is essential because management strategies differ significantly [57].

6.7 Diagnostic Challenges in Adolescents

Diagnosing PCOD during adolescence is particularly difficult.

Physiological pubertal changes often resemble pathological features such as:

• Irregular menstruation
• Acne
• Multifollicular ovaries

Experts recommend cautious interpretation and repeated follow-up before establishing diagnosis [58].

Overdiagnosis can result in unnecessary anxiety, whereas delayed diagnosis may postpone intervention.

6.8 Emerging Diagnostic Biomarkers

Research is exploring novel biomarkers for earlier and more accurate diagnosis.

Promising candidates include:

Anti-Müllerian Hormone

Often elevated in PCOD due to increased follicle number.

Inflammatory cytokines

Reflect metabolic disturbance.

MicroRNAs

Potential molecular signatures.

Metabolomic markers

Provide insight into disease phenotype [59].

These biomarkers may improve diagnostic precision in the future.

6.9 Role of Artificial Intelligence in Diagnosis

Artificial intelligence and machine learning are emerging tools in PCOD diagnosis.

Applications include:

• Ultrasound image analysis
• Hormonal pattern recognition
• Risk prediction modeling
• Phenotype classification

AI-based systems may improve early detection and reduce diagnostic variability [60].

6.10 Importance of Early Diagnosis

Timely diagnosis allows:

• Early lifestyle intervention
• Prevention of infertility
• Reduction of metabolic complications
• Improved quality of life

A comprehensive diagnostic approach integrating clinical, biochemical, and imaging evaluation remains essential for optimal patient management.

7. Conventional Therapeutic Strategies